Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting
Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…Abstract Number: 465 • 2014 ACR/ARHP Annual Meeting
18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
Background/Purpose: Post-marketing surveillance is an important part of monitoring adverse events (AEs) following the approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor…Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA). In a phase 2b study, baricitinib treatment resulted…Abstract Number: 39 • 2014 ACR/ARHP Annual Meeting
Human CD14+ Monocytes Stimulated with a Combination of TNFα and IL-6 Differentiate into Osteoclast-like Cells with Bone-Resorption Activity
Background/Purpose Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting
Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome
Background/Purpose: We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…Abstract Number: 1434 • 2013 ACR/ARHP Annual Meeting
Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Background/Purpose: Bayesian style network meta-analyses and mixed treatment comparisons help address potential bias from effect modifying trial covariates within indirect comparisons and are theoretically easier…Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »